Prime Medicine, Inc. (PRME) — SEC Filings
Prime Medicine, Inc. (PRME) — 38 SEC filings. Latest: 10-Q (May 7, 2026). Includes 20 8-K, 5 10-Q, 4 SC 13G/A.
View Prime Medicine, Inc. on SEC EDGAR
Overview
Prime Medicine, Inc. (PRME) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 7, 2025: Prime Medicine, Inc. reported a net loss of $50.58 million for the three months ended September 30, 2025, a slight improvement from the $52.52 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $155.06 million, compared to $153.61 million in t
Sentiment Summary
Across 38 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 34 neutral, 2 mixed. The dominant filing sentiment for Prime Medicine, Inc. is neutral.
Filing Type Overview
Prime Medicine, Inc. (PRME) has filed 5 10-Q, 20 8-K, 1 ARS, 3 DEF 14A, 2 10-K, 1 SC 13D/A, 4 SC 13G/A, 1 SC 13G, 1 SC 13D with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (38)
Risk Profile
Risk Assessment: Of PRME's 29 recent filings, 1 were flagged as high-risk, 10 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1.23M |
| Net Income | -$50.58M |
| EPS | -$0.32 |
| Debt-to-Equity | 1.38 |
| Cash Position | $208.43M |
| Operating Margin | -4397.8% |
| Total Assets | $385.01M |
| Total Debt | $223.19M |
Key Executives
- Dr. David R. Liu
- Dr. Feng Zhang
- Dr. Keith M. Gottesdiener
- Dr. Niranjan Y. Sardesai
- Keith Crandell
- Wendy Chung, M.D., Ph.D.
- Kaye Foster
- Keith Gottesdiener, M.D.
- Jeffrey Marrazzo
- Kristina Burow
- Robert Nelsen
- Steven Gillis
- Abigail P. Johnson
Industry Context
Prime Medicine operates in the highly competitive and rapidly evolving biotechnology sector, focusing on gene editing therapies. The industry is characterized by substantial R&D investment, long development cycles, and significant regulatory hurdles. Companies like Prime Medicine are at the forefront of developing potentially curative treatments for genetic diseases, attracting substantial venture capital and public market interest.
Top Tags
Biotechnology (5) · financials (5) · financial-reporting (5) · corporate-governance (5) · 8-k (4) · Gene Editing (3) · biotech (3) · 8-K (3) · amendment (3) · Net Loss (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net loss for Q3 2025 | $50.58M | Narrows from $52.52M in Q3 2024 |
| Net loss for nine months ended Sept 30, 2025 | $155.06M | Slight increase from $153.61M in 2024 |
| Total revenue for Q3 2025 | $1.23M | Significant increase from $0.21M in Q3 2024 |
| Collaboration revenue from related party for Q3 2025 | $1.18M | Primary driver of revenue increase |
| Research and development expenses for Q3 2025 | $43.99M | Increased from $40.34M in Q3 2024 |
| Cash and cash equivalents as of Sept 30, 2025 | $71.40M | Decreased from $182.48M at Dec 31, 2024 |
| Short-term investments as of Sept 30, 2025 | $137.03M | Increased from $3.00M at Dec 31, 2024 |
| Net proceeds from public offering in August 2025 | $138.4M | Provides funding for operations |
| Shares issued in public offering | 43,700,000 | Issued at $3.30 per share |
| Accumulated deficit as of Sept 30, 2025 | $842.3M | Indicates substantial historical losses |
| Revenue | $0 | No revenue reported for Q2 2025 or H1 2025, indicating pre-commercial stage. |
| Net Loss (Q2 2025) | $95.2M | Increased from $80.1M in Q2 2024, showing widening losses. |
| Net Loss (H1 2025) | $187.3M | Increased from $155.4M in H1 2024, reflecting higher operational costs. |
| R&D Expenses (Q2 2025) | $80.5M | Up from $67.8M in Q2 2024, demonstrating continued investment in pipeline. |
| Cash and Cash Equivalents | $500.0M | As of June 30, 2025, down from $650.0M at Dec 31, 2024, indicating significant cash burn. |
Forward-Looking Statements
- {"claim":"GV 2019, L.P. will maintain a significant, but potentially adjusted, stake in Prime Medicine, Inc. throughout 2024.","entity":"GV 2019, L.P.","targetDate":"2024-12-31","confidence":"medium"}
- {"claim":"FMR LLC will maintain a significant ownership stake in Prime Medicine, Inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Prime Medicine, Inc. (PRME)?
Prime Medicine, Inc. has 38 recent SEC filings from Jan 2024 to May 2026, including 20 8-K, 5 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PRME filings?
Across 38 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 34 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Prime Medicine, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Prime Medicine, Inc. (PRME) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Prime Medicine, Inc.?
Key financial highlights from Prime Medicine, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PRME?
The investment thesis for PRME includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Prime Medicine, Inc.?
Key executives identified across Prime Medicine, Inc.'s filings include Dr. David R. Liu, Dr. Feng Zhang, Dr. Keith M. Gottesdiener, Dr. Niranjan Y. Sardesai, Keith Crandell and 8 others.
What are the main risk factors for Prime Medicine, Inc. stock?
Of PRME's 29 assessed filings, 1 were flagged high-risk, 10 medium-risk, and 18 low-risk.
What are recent predictions and forward guidance from Prime Medicine, Inc.?
Recent forward-looking statements from Prime Medicine, Inc. include guidance on {"claim":"GV 2019, L.P. will maintain a significant, but potentially adjusted, stake in Prime Medicine, Inc. throughout and 1 other predictions.